|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bernadach M, Lapeyre M, Dillies AF, Miroir
J, Moreau J, Kwiatkowski F, Pham-Dang N, Saroul N, Durando X and
Biau J: Toxicity of docetaxel, platine, 5-fluorouracil-based
induction chemotherapy for locally advanced head and neck cancer:
The importance of nutritional status. Cancer Radiother. 23:273–280.
2019.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zu M, Ma L, Zhang X, Xie D, Kang Y and
Xiao B: Chondroitin sulfate-functionalized polymeric nanoparticles
for colon cancer-targeted chemotherapy. Colloids Surf B
Biointerfaces. 177:399–406. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ishaq M, Khan MA, Sharma K, Sharma G,
Dutta RK and Majumdar S: Gambogic acid induced oxidative stress
dependent caspase activation regulates both apoptosis and autophagy
by targeting various key molecules (NF-κB, Beclin-1, p62 and NBR1)
in human bladder cancer cells. Biochim Biophys Acta.
1840:3374–3384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang J and Yuan Z: Gambogic acid
sensitizes ovarian cancer cells to doxorubicin through ROS-mediated
apoptosis. Cell Biochem Biophys. 67:199–206. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang S, Wang L, Chen M and Wang Y:
Gambogic acid sensitizes resistant breast cancer cells to
doxorubicin through inhibiting P-glycoprotein and suppressing
survivin expression. Chem Biol Interact. 235:76–84. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang W, Wang X, Shi C, Guo D, Xu G, Wang
L, Bodman A and Luo J: Fine-tuning vitamin E-containing
telodendrimers for efficient delivery of gambogic acid in colon
cancer treatment. Mol Pharm. 12:1216–1229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Danielsen SA, Eide PW, Nesbakken A, Guren
T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in
colorectal cancer. Biochim Biophys Acta. 1855:104–121.
2015.PubMed/NCBI
|
|
9
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Faes S and Dormond O: PI3K and AKT:
Unfaithful partners in cancer. Int J Mol Sci. 16:21138–21152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang YL, Zhou PJ, Wei L, Li W, Ji Z, Fang
YX and Gao WQ: MicroRNA-7 inhibits the stemness of prostate cancer
stem-like cells and tumorigenesis by repressing KLF4/PI3K/Akt/p21
pathway. Oncotarget. 6:24017–24031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng L, Zhang Y, Liu Y, Zhou M, Lu Y,
Yuan L, Zhang C, Hong M, Wang S and Li X: MiR-106b induces cell
radioresistance via the PTEN/PI3K/AKT pathways and p21 in
colorectal cancer. J Transl Med. 13:2522015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li W, Liu Z, Zhao C and Zhai L: Binding of
MMP-9-degraded fibronectin to β6 integrin promotes invasion via the
FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast
cancer. Oncol Rep. 34:1345–1352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu Q, Li C and Yu L: Gambogic acid
inhibits spinal cord injury and inflammation through suppressing
the p38 and Akt signaling pathways. Mol Med Rep. 17:2026–2032.
2018.PubMed/NCBI
|
|
16
|
Wu X, Long L, Liu J, Zhang J, Wu T, Chen
X, Zhou B and Lv TZ: Gambogic acid suppresses inflammation in
rheumatoid arthritis rats via PI3K/Akt/mTOR signaling pathway. Mol
Med Rep. 16:7112–7118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan D, Zhang B, Yao J, Liu Y, Sun J, Ge
C, Peng S and Fang J: Gambogic acid induces apoptosis in
hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic
thioredoxin reductase. Free Radic Biol Med. 69:15–25. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi X, Chen X, Li X, Lan X, Zhao C, Liu S,
Huang H, Liu N, Liao S, Song W, et al: Gambogic acid induces
apoptosis in imatinib-resistant chronic myeloid leukemia cells via
inducing proteasome inhibition and caspase-dependent Bcr-Abl
downregulation. Clin Cancer Res. 20:151–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang LH, Yang JY, Yang SN, Li Y, Ping GF,
Hou Y, Cui W, Wang ZZ, Xiao W and Wu CF: Suppression of NF-κB
signaling and P-glycoproteins function by gambogic acid
synergistically potentiates adriamycin-induced apoptosis in lung
cancer. Curr Cancer Drug Targets. 14:91–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chi Y, Zhan XK, Yu H, Xie GR, Wang ZZ,
Xiao W, Wang YG, Xiong FX, Hu JF, Yang L, et al: An open-labeled,
randomized, multicenter phase II a study of gambogic acid injection
for advanced malignant tumors. Chin Med J (Engl). 126:1642–1646.
2013.PubMed/NCBI
|
|
21
|
Wang X and Chen W: Gambogic acid is a
novel anti-cancer agent that inhibits cell proliferation,
angiogenesis and metastasis. Anticancer Agents Med Chem.
12:994–1000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei F, Zhang T, Yang Z, Wei JC, Shen HF,
Xiao D, Wang Q, Yang P, Chen HC, Hu H, et al: Gambogic acid
efficiently kills stem-like colorectal cancer cells by upregulating
ZFP36 expression. Cell Physiol Biochem. 46:829–846. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao G, Bian Y, Qian H, Yang M, Hu J, Li L,
Yu L, Liu B and Qian X: Gambogic acid regulates the migration and
invasion of colorectal cancer via microRNA-21-mediated activation
of phosphatase and tensin homolog. Exp Ther Med. 16:1758–1765.
2018.PubMed/NCBI
|
|
24
|
Toren P and Zoubeidi A: Targeting the
PI3K/Akt pathway in prostate cancer: Challenges and opportunities
(review). Int J Oncol. 45:1793–1801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J, Shao R, Li F, Monteiro M, Liu JP,
Xu ZP and Gu W: PI3K/Akt/mTOR pathway dual inhibitor BEZ235
suppresses the stemness of colon cancer stem cells. Clin Exp
Pharmacol Physiol. 42:1317–1326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu S, Ren C, Liu Y and Epner DE: PI3K-Akt
signaling is involved in the regulation of p21(WAF/CIP) expression
and androgen-independent growth in prostate cancer cells. Int J
Oncol. 28:245–251. 2006.PubMed/NCBI
|
|
27
|
Yeo D, He H, Baldwin GS and Nikfarjam M:
The role of p21-activated kinases in pancreatic cancer. Pancreas.
44:363–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei CY, Tan QX, Zhu X, Qin QH, Zhu FB, Mo
QG and Yang WP: Expression of CDKN1A/p21 and TGFBR2 in breast
cancer and their prognostic significance. Int J Clin Exp Pathol.
8:14619–14629. 2015.PubMed/NCBI
|
|
29
|
Li J, Li Z, Kan Q, Sun S, Li Y and Wang S:
Association of p21 3′UTR gene polymorphism with cancer risk:
Evidence from a meta-analysis. Sci Rep. 5:131892015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakayama H, Ohuchida K, Yonenaga A, Sagara
A, Ando Y, Kibe S, Takesue S, Abe T, Endo S, Koikawa K, et al:
S100P regulates the collective invasion of pancreatic cancer cells
into the lymphatic endothelial monolayer. Int J Oncol. 55:211–222.
2019.PubMed/NCBI
|
|
31
|
Kapali AS, George NA, Iype EM, Thomas S,
Varghese BT, Balagopal PG and Sebastian P: Retrospective outcome
analysis of Buccal mucosal and lower alveolar squamous cell
carcinoma from a high-volume tertiary cancer Centre. Indian J Surg
Oncol. 10:286–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Iochmann S, Bléchet C, Chabot V, Saulnier
A, Amini A, Gaud G, Gruel Y and Reverdiau P: Transient RNA
silencing of tissue factor pathway inhibitor-2 modulates lung
cancer cell invasion. Clin Exp Metastasis. 26:457–467. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Safranek J, Pesta M, Holubec L, Kulda V,
Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska
V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung
tissue of patients with non-small cell lung cancer (NSCLC) and
benign pulmonary disease. Anticancer Res. 29:2513–2518.
2009.PubMed/NCBI
|
|
34
|
Yuan H, Yang P, Zhou D, Gao W, Qiu Z, Fang
F, Ding S and Xiao W: Knockdown of sphingosine kinase 1 inhibits
the migration and invasion of human rheumatoid arthritis
fibroblast-like synoviocytes by down-regulating the PI3K/AKT
activation and MMP-2/9 production in vitro. Mol Biol Rep.
41:5157–5165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan Z, Duan X, Cai H, Wang L, Li M, Qu J,
Li W, Wang Y and Wang J: Curcumin inhibits the invasion of lung
cancer cells by modulating the PKCα/Nox-2/ROS/ATF-2/MMP-9 signaling
pathway. Oncol Rep. 34:691–698. 2015. View Article : Google Scholar : PubMed/NCBI
|
